BSI-502, a bispecific antibody targeting TSLP and IL4R, is in the pre-clinical stage. In a completed, proof-of-concept, single-arm Phase IIa study, BSI-045B demonstrated a pharmacodynamic profile ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback